We have developed new strategies for anti-angiogenic therapy in uterine cervical cancers, uterine endometrial cancers and ovarian cancers in order to avoid recruitment of alternative pathways as a form of tolerance, based on the expression manners of main angiogenic factors with a mediator, and one angiogenic transcription factor.